To assess the prognostic value of circulating anti-TERT Th1 immunity and exhausted PD-1+/TIM-3+ T cells in this cohort of treatment-naive NSCLC, we considered two groups of patients with low versus high circulating rates of these two immune parameters (see details in the Methods section and Supplementary Table 3). Here, TERT is linked to non-small cell lung carcinoma.